Heron Therapeutics, Inc.
HRTX
$2.48
$0.093.77%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 134.16% | 80.61% | 78.04% | 90.36% | 46.03% |
| Total Depreciation and Amortization | -18.74% | -20.08% | -13.26% | -4.04% | -9.61% |
| Total Amortization of Deferred Charges | 84.05% | 416.44% | 176.92% | 174.51% | 226.00% |
| Total Other Non-Cash Items | -48.22% | -53.73% | -47.01% | -61.89% | -61.08% |
| Change in Net Operating Assets | -318.32% | -50.13% | -986.53% | -1,811.36% | 129.45% |
| Cash from Operations | -579.84% | 136.73% | 83.05% | 61.78% | 106.54% |
| Capital Expenditure | -155.20% | 45.65% | -129.14% | -- | 39.61% |
| Sale of Property, Plant, and Equipment | 107.69% | -- | -- | -- | 333.33% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 239.89% | 119.62% | -80.11% | -96.55% | -453.58% |
| Cash from Investing | 229.22% | 117.10% | -84.51% | -96.53% | -537.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 110.45% | -99.95% | -28.55% | -- | -69.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 97.14% | 105.29% | 99.07% |
| Cash from Financing | 112.56% | -99.97% | 54.23% | 105.29% | -54.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.99% | -65.63% | 84.85% | -170.16% | 82.37% |
